UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 


 

FORM 8-K

 

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): January 31, 2012

 

AFFYMAX, INC.

(Exact name of registrant as specified in charter)

 

Delaware

 

001-33213

 

77-0579396

(State or other jurisdiction of

 

(Commission File Number)

 

(I.R.S. Employer Identification No.)

incorporation)

 

 

 

 

 

4001 Miranda Avenue
Palo Alto, California 94304
(Address of principal executive offices and zip code)

 

Registrant’s telephone number, including area code: (650) 812 -8700

 


 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

o            Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o            Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12(b))

 

o            Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o            Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 



 

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

On January 31, 2012, the Board of Directors of Affymax, Inc. (the “Company”) approved increases in annual base salaries for 2012, option grants, restricted stock unit (“RSU”) grants and cash bonuses related to 2011 performance for the following executive officers:

 

Name and Position

 

2012 Salary
Increase

 

New 2012 Base
Salary

 

Options
Granted

 

RSUs Granted

 

Bonus

 

John A. Orwin
Chief Executive Officer

 

$

50,000

 

$

560,000

 

140,000

 

25,000

 

$

397,800

 

Herb Cross
Chief Financial Officer

 

$

30,000

 

$

330,000

 

60,000

 

10,000

 

$

128,625

 

Anne-Marie Duliege, M.D., M.S.
Chief Medical Officer

 

$

11,450

 

$

393,133

 

48,750

 

8,125

 

$

163,647

 

Robert Venteicher, Ph.D.,
Senior Vice President,
Technical Operations

 

$

3,283

 

$

331,570

 

24,375

 

4,063

 

$

140,753

 

 

The bonus payouts are based on the individual performance of each executive as well as achievement against the corporate objectives.  In the case of the Chief Executive Officer, the bonus payout is based solely on achievement against the corporate objectives.  Corporate objectives are established at the beginning of each year and are intended to result in increased stockholder value.  The Board of Directors determined that the Company significantly exceeded the corporate objectives established for 2011.

 

In addition, the grant of options (vesting over 4 years) and RSUs (vesting over 3 years) recognize the individual performance of each executive, and further align the interests of management and stockholders in the long-term success of the Company.  We will provide a more detailed discussion of the corporate objectives and their achievement, for both the Company and the named executive officers, including our compensation philosophy, in our Proxy Statement.

 

2



 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

 

 

AFFYMAX, INC .

 

 

 

 

Dated: February 2, 2012

By:

/s/ Grace U. Shin

 

 

Grace U. Shin
General Counsel

 

3